Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. Issue 10 (7th January 2014)

• Record Type: Journal Article
• Authors: Tajiri, Hitoshi; Tanaka, Yasuhito; Takano, Tomoko; Suzuki, Mitsuyoshi; Abukawa, Daiki; Miyoshi, Yoko; Shimizu, Toshiaki; Brooks, Stephen
• Is Part Of: Hepatology research. Volume 44:Issue 10(2014:Oct.)
• Page Start: E38
• Page End: E44
• Publication Date: 2014-01-07
• Subjects: Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.12206
• Languages: English
• ISSNs: 1386-6346

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hepr12206-sec-0001" sec-type="section"> <title>Aim</title> <p>The objective of the current study was to find baseline predictive factors of response to therapy with pegylated interferon and ribavirin (PEG‐IFN/RBV therapy) in children and adolescents with chronic hepatitis C.</p> </sec> <sec id="hepr12206-sec-0002" sec-type="section"> <title>Methods</title> <p> <italic>IL28B</italic> genotype and mutations in the core of hepatitis C virus (HCV) were analyzed in 30 patients treated with PEG‐IFN/RBV for HCV infection. The initial rate of decrease in the viral load was assessed during the first 2 weeks of treatment.</p> </sec> <sec id="hepr12206-sec-0003" sec-type="section"> <title>Results</title> <p> <italic>IL28B</italic> major allele was seen more frequently in patients with sustained virologic response (SVR) than in non‐SVR patients (<italic>P</italic> < 0.001). There was no difference between these two groups in frequency of Core 70 mutation. Among patients with genotype‐1, SVR was achieved in more patients (<italic>P</italic> = 0.007) in the <italic>IL28B</italic> major allele group than in those in the minor allele group. The early decrements in the viral load (log/2 weeks) were 3.80 ± 0.86 in the genotype‐2 major allele group, 1.82 ± 0.84 in the genotype‐1 major allele group, and 0.41 ± 0.33 in the genotype‐1 minor allele group.</p> </sec> <sec id="hepr12206-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Among pediatric patients with HCV infection the effectiveness of PEG‐IFN/RBV therapy may be lower in the group with genotype‐1 <italic>IL28B</italic> minor alleles than in other groups with <italic>IL28B</italic> major allele. Treatment strategy should be carefully implemented in patients with <italic>IL28B</italic> unfavorable type.</p> </sec> </abstract>